OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to...

Cijeli opis

Bibliografski detalji

Glavni autori:	Patrizia Nanni, Carla De Giovanni, Alessia Burocchi, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Ivano Arioli, Mario P. Colombo, Pier-Luigi Lollini
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2018-08-01
Serija:	OncoImmunology
Teme:	cancer vaccine her2/neu immunoprevention mammary cancer ox40
Online pristup:	http://dx.doi.org/10.1080/2162402X.2018.1465164
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!